Prediction of short-term atrial fibrillation risk using primary care electronic health records

Ramesh Nadarajah 1,2, Jianhua Wu 3,4, David Hogg,4 Keerthenan Raveendra,5 Yoko M Nakao 6,7, Kazuhiro Nakao,1,2 Ronen Arbel 6,7, Moti Haim,8,9 Doron Zahger,9,10 John Parry,11 Chris Bates 11, Campbel Cowan,12 Chris P Gale1,12

ABSTRACT

Objective Atrial fibrillation (AF) screening by age achieves a low yield and misses younger individuals. We aimed to develop an algorithm in nationwide routinely collected primary care data to predict the risk of incident AF within 6 months (Future Innovations in Novel Detection of Atrial Fibrillation (FIND-AF)).

Methods We used primary care electronic health record data from individuals aged ≥30 years without known AF in the UK Clinical Practice Research Datalink-GOLD dataset between 2 January 1998 and 30 November 2018, randomly divided into training (80%) and testing (20%) datasets. We trained a random forest classifier using age, sex, ethnicity and comorbidities. Prediction performance was evaluated in the testing dataset with internal bootstrap validation with 200 samples, and compared against the CHA2DS2-VASC (Congestive heart failure, Hypertension, Age ≥75 (2 points), Stroke/transient ischaemic attack/thromboembolism (2 points), Vascular disease, Age 65–74, Sex category) and C2HEST (Coronary artery disease/Chronic obstructive pulmonary disease (1 point each), Hypertension, Elderly (age ≥75, 2 points), Systolic heart failure, Thyroid disease (hyperthyroidism)) scores. Cox proportional hazard models with competing risk of death were fit for incident AF identified a cohort of higher-risk individuals younger than 65 years of age, and higher predicted AF risk was associated with elevated incident AF in the short and long term.

INTRODUCTION

Atrial fibrillation (AF) is a major public health issue. There are now more new cases of AF diagnosed each year in the English National Health Service (NHS) than the four most common causes of cancer combined. Moreover, it is estimated that up to 35% of disease burden remains undiagnosed, and 15% of strokes occur in the context of undiagnosed AF.
Early detection of AF may permit the initiation of oral anticoagulation to reduce embolic stroke risk, and early antiarrhythmic therapy to reduce the risk of death and stroke. Accordingly, early AF detection is a key cardiovascular priority in the UK NHS Long Term Plan, and the European Society of Cardiology recommends opportunistic screening by pulse palpation or ECG rhythm strip in persons aged ≥65 years and systematic ECG screening in those aged ≥75 years. However, there is an increasing cohort of individuals aged younger than 65 years who are being diagnosed with AF and are eligible for anticoagulation.

A large proportion of the population is registered in primary care with a routinely collected electronic health record (EHR). An algorithm that uses routinely collected EHR data to calculate AF risk could give a scalable, efficient and fair approach to targeting AF detection. However, previous algorithms tested in late AF risk could give a scalable, efficient and fair approach to targeting AF detection. Previous algorithms developed using traditional regression techniques show only moderate prediction performance by sex and ethnicity. Third, many algorithms developed using traditional regression techniques show only moderate prediction performance by sex and ethnicity. Fourth, algorithms often require variables frequently missing from routinely collected data such as height, weight and blood pressure thereby restricting the population to which they can be applied.

Therefore, our objective was to train and test an algorithm (Future Innovations in Novel Detection of Atrial Fibrillation, FIND-AF) that predicts an individual’s risk of AF in the next 6 months using routinely recorded data in primary care EHRs. We compared performance against other AF prediction algorithms and investigated for variation in performance by sex and ethnicity.

METHODS

Study design and population

In this population-based study, we used primary care EHRs from the UK Clinical Practice Research Datalink (CPRD)-GOLD database. CPRD is one of the largest databases of longitudinal medical records from primary care worldwide and contains anonymised patient data from approximately 7% of the UK population. CPRD-GOLD represents the UK population in terms of age, sex and ethnicity, and has been used to develop algorithms for predicting AF. Data collection happens as part of routine clinical care in participating practices and patients are included in the primary care dataset from their first until their last contact with a participating practice. Diagnostic coding for AF in CPRD has been shown to be consistent and valid, with a positive predictive value (PPV) of 98%. All individuals in the CPRD dataset were linked to Hospital Episode Statistics (HES) Admitted Patient Care (APC) records to obtain comprehensive coverage of AF cases diagnosed in secondary care. We included all adults registered at practices within CPRD who were ≥30 years of age at entry with no history of AF from either data source and at least 1-year follow-up between 2 January 1998 and 30 November 2018. Individuals were censored to a diagnosis of AF (or atrial flutter (AFL)), since it has similar thromboembolic risk and anticoagulation guidelines, withdrawal from CPRD or 6 months, whichever came first. Diagnoses of AF or AFL in primary care were identified using Read codes in CPRD and in secondary care with the 10th revision of the International Statistical Classification of Diseases and Related Health Problems codes in HES-APC (online supplemental table 3). Individuals were randomly split 4:1 to establish a training dataset (80%) and a testing dataset (20%) using the Mersenne twister pseudorandom number generator.

We followed the Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis reporting guideline and the CODE-EHR best-practice framework for using structured electronic healthcare records in clinical research.

FIND-AF algorithm development

A random forest (RF) classifier was trained to predict AF at 6 months. Our systematic review evidenced strong discriminative performance for AF prediction using RF across different EHR datasets. RF is a machine learning method consisting of many individual decision trees that operate as an ensemble. FIND-AF was trained using 10-fold cross-validation on the full training set (full details available in online supplemental methods).

To create an algorithm that could be implemented at scale in national primary care EHRs, we restricted candidate variables to age, sex, comorbidities (72 binary variables, indicating presence or absence of recorded diagnosis) and ethnicity (six categories; online supplemental table 6). Observations and laboratory results were not included. Ethnicity information is routinely collected in the UK NHS and so has increasingly high completeness, and we included an ‘ethnicity unrecorded’ category where it was unavailable because missingness was considered to be informative. Predictor variables were selected a priori from systematic review of variables included in previous AF risk prediction algorithms, plus an updated literature review (online supplemental tables 4–6). Diagnostic code lists only included the primary care coding system (Read codes), ensuring that only information readily available within a primary care EHR could be incorporated within the algorithm. Concordantly, our entire analytical cohort had no missing data for any of the predictor variables and the algorithm could be applied to all records.

Statistical analyses

The baseline characteristics are summarised by incident AF status. Continuous variables were reported as mean±SD. Categorical variables were reported as frequencies with corresponding percentages.

The degree of variation of each feature in FIND-AF to classification was calculated using the mean decrease in the Gini coefficient, a measure of how each variable contributes to the homogeneity of nodes and leaves in the resulting RF.

Model performance of FIND-AF was determined using the full holdout test set with internal bootstrap validation with 200 samples and compared with a multivariable logistic regression (MLR) model developed with backward model selection with Akaike information criterion. Performance was compared with the CHA2DS2-VASc score was originally developed to predict stroke risk in individuals with AF, and the CHA2DS2-VASc score for Asian people without structural heart disease. These algorithms are robust to missing data in routinely collected primary care EHRs and have been tested for AF risk prediction in European cohorts (online supplemental table 2). Other algorithms that can only be applied to a minority of European primary care

EHRs (Pfizer-AI, CHARGE-AF) were not considered. The area under the receiver operating characteristic (AUROC) curve was used to evaluate predictive ability (concordance index) with 95% CIs calculated using the DeLong method. Youden Index was established for the outcome measure as a method of empirically identifying the optimal dichotomous cut-off to assess sensitivity, specificity, PPV and negative predictive value (NPV). Youden Index was calculated and optimised for each test set for each score to derive the optimal cut-off threshold. Calibration was assessed by plotting predicted AF risk against observed AF incidence and by the calibration slope. We calculated the Brier score, a measure of both discrimination and calibration, by taking the mean squared difference between predicted probabilities and the observed outcome. To assess the clinical impact of using FIND-AF as opposed to other risk prediction scores, we calculated the net reclassification index at 0.4% AF risk threshold (the average 6-month incidence rate in the cohort) and conducted a decision curve analysis.

We investigated the performance of FIND-AF, CHA₂DS₂-VASc and C_HEST within relevant subgroups defined by sex, ethnicity (white vs black vs Asian vs other non-white ethnic minorities) and age (≥65 years and ≥75 years). We plotted Kaplan-Meier plots for individuals identified as higher and lower FIND-AF-predicted risk of AF to assess the event rate for AF censored at 10 years, and calculated the HR for AF between higher and lower FIND-AF-predicted risk of AF using the Cox proportional hazard model with adjustment for the competing risk of death. We used R V4.1.0 for all analyses.

Patient and public involvement
The Arrhythmia Alliance, an AF association, provided input on the FIND-AF scientific advisory board. The FIND-AF patient and public involvement group have given input to reporting and dissemination plans of the research.

RESULTS
Patient population
There were 2 081 139 individuals registered in our UK primary care cohort (1 664 911 in the training dataset, 416 228 in testing dataset), with average age 49.9 years (SD 15.4), 50.7% women and 86.7% white. Baseline characteristics and clinical outcomes were similar in the training and testing datasets (online supplemental table 7). Within 6 months, 7386 individuals (0.4%) were recorded as having AF. Those who developed AF were older and had a higher prevalence of baseline comorbidities than individuals who did not develop AF (table 1). Of new cases, 1546 (20.9%) were younger than 65 years old.

Prediction factors and model accuracy
According to mean decrease in the Gini coefficient, age contributed the most to the prediction, followed by ethnicity and history of heart failure (figure 1). AF discrimination and accuracy of predictions, by AUROC and Brier scores, were better using FIND-AF than the MLR, CHA₂DS₂-VASc and C_HEST algorithms (table 2 and figure 2). Sensitivity was highest for the CHA₂DS₂-VASc algorithm, but specificity lowest.

According to the Youden Index, the optimal cut-off was 0.0032, leading to a sensitivity of 78% and a specificity of 73%, with a PPV of 2.5% and NPV of 99.8%. The low incidence of AF over 6 months led to similar values for PPV and NPV across the algorithms. Of the algorithms, FIND-AF was the most calibrated (calibration slope 0.782 (95% CI 0.743 to 0.824), table 2 and online supplemental figure 1), yet showed underestimation of risk in the mid-risk strata and overestimation in the highest risk strata.

Risk classification
Of the 416 228 individuals in the testing set, 82 942 (19.9%) were classified as higher risk using FIND-AF, 84 282 (20.2%) using the CHA₂DS₂-VASc score and 84 542 (20.3%) using the C_HEST score, respectively. Net reclassification analyses at the 0.4% risk threshold demonstrated modestly favourable reclassification using FIND-AF as opposed to using CHA₂DS₂-VASc (net reclassification 0.032, 95% CI 0.029 to 0.051) and strong favourable reclassification using FIND-AF as opposed to using C_HEST (net reclassification 0.113, 95% CI 0.098 to 0.135; online supplemental table 8). In a decision curve analysis, FIND-AF had a superior net benefit compared with the CHA₂DS₂-VASc and C_HEST risk scores across all threshold probabilities (online supplemental figure 2).

Of the 82 942 individuals identified as higher risk by FIND-AF, 3483 were <65 years of age, of whom 3448 had a CHA₂DS₂-VASc score of at least 1. The incidence rate of AF in routine clinical practice at 6 months was 20-fold higher among individuals identified as a higher predicted risk of AF by FIND-AF compared with individuals identified as lower risk (2.0% vs 0.1%). In routine clinical practice, 1 in every 71 individuals aged ≥65 years were diagnosed with AF within 6 months, 1 in every 58 individuals aged ≥75 years and 1 in every 40 individuals identified at higher predicted AF risk.

Higher predicted AF risk was also associated with increased long-term AF occurrence. Within 5 and 10 years, respectively, 5.1% and 11.9% of the higher predicted risk cohort had been diagnosed with AF, with an 8.75-fold increased hazard (95% CI 8.44 to 9.06) relative to individuals at lower predicted risk (figure 3).

Table 1  Baseline characteristics of analytical cohort with and without atrial fibrillation (AF)

<table>
<thead>
<tr>
<th>Incidence AF</th>
<th>No AF</th>
<th>AF</th>
</tr>
</thead>
<tbody>
<tr>
<td>n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, years</td>
<td>49.82 (15.37)</td>
<td>73.72 (12.62)</td>
</tr>
<tr>
<td>Sex (women)</td>
<td>1 051 942 (50.7)</td>
<td>3619 (49.0)</td>
</tr>
<tr>
<td>Comorbidities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>247 436 (11.9)</td>
<td>2887 (39.1)</td>
</tr>
<tr>
<td>Heart failure</td>
<td>13 717 (0.7)</td>
<td>650 (8.8)</td>
</tr>
<tr>
<td>Dyslipidaemia</td>
<td>60 357 (2.9)</td>
<td>532 (7.2)</td>
</tr>
<tr>
<td>Hyperthyroidism</td>
<td>16 147 (0.8)</td>
<td>155 (2.1)</td>
</tr>
<tr>
<td>COPD</td>
<td>24 962 (1.2)</td>
<td>461 (6.2)</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>29 359 (1.4)</td>
<td>449 (6.1)</td>
</tr>
<tr>
<td>Anaemia</td>
<td>66 844 (3.2)</td>
<td>501 (6.8)</td>
</tr>
<tr>
<td>Cancer</td>
<td>72 621 (3.5)</td>
<td>887 (12.0)</td>
</tr>
<tr>
<td>Mean CHA₂DS₂-VASc score (SD)</td>
<td>0.97 (1.03)</td>
<td>2.72 (1.42)</td>
</tr>
</tbody>
</table>

CHA₂DS₂-VASc, Congestive heart failure, Hypertension, Age >75 years (2 points), Stroke/transient ischaemic attack/thromboembolism (2 points), Vascular disease, Age 65–74 years, Sex category; COPD, chronic obstructive pulmonary disease; TIA, transient ischaemic attack.
Arrhythmias and sudden death

Model performance in clinically relevant subgroups

FIND-AF discrimination performance remained strong in both sexes, whereas for the CHA₂DS₂-VASc and C_HEST scores, performance was better in men than women (Table 3). The scores performed differently across ethnic groups. In black individuals, AF discrimination was highest for CHA₂DS₂-VASc, and in white and Asian individuals, FIND-AF had the strongest discrimination performance.

DISCUSSION

In this population-based study, we trained a machine learning algorithm (FIND-AF) on more than 1.5 million individuals registered in UK primary care to predict the risk of incident AF within the next 6 months (Figure 4). When tested in over 400,000 individuals, FIND-AF demonstrated good predictive accuracy, which was superior to other risk scores and robust in both sexes and across ethnic groups. FIND-AF identified a cohort of younger people at higher risk of AF and more efficiently identified individuals diagnosed with AF within 6 months compared with age-based risk stratification. Finally, short-term predicted AF risk also translated to long-term AF occurrence.

Current approaches to targeting investigation for undiagnosed AF are based on age. Our analysis demonstrated that one-fifth of newly detected AF cases within 6 months occur in people aged ≤65 years, emphasising the opportunity lost when enhanced AF investigation is restricted to older populations. ECGs can be used to accurately predict AF risk, but they are not widely available in the community, whereas 98% of the UK population are registered in primary care with an accompanying EHR. Our meta-analysis of AF prediction algorithms using EHRs demonstrated that algorithms developed using traditional regression techniques provided only moderate discrimination performance. In our study, a machine learning prediction algorithm (FIND-AF) outperformed the C_HEST and CHA₂DS₂-VASc scores.

For a machine learning prediction algorithm to be useful in clinical practice, it must be implementable within the clinical workflow, provide prediction that meaningfully informs decision-making and engender confidence in how outputs were

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Performance for 6-month incident AF with optimal threshold determined by Youden Index</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Algorithm</strong></td>
<td>FIND-AF</td>
</tr>
<tr>
<td><strong>AUROC (95% CI)</strong></td>
<td>0.824 (0.814 to 0.834)</td>
</tr>
<tr>
<td><strong>Sensitivity (95% CI)</strong></td>
<td>0.781 (0.731 to 0.829)</td>
</tr>
<tr>
<td><strong>Specificity (95% CI)</strong></td>
<td>0.731 (0.693 to 0.771)</td>
</tr>
<tr>
<td><strong>PPV (%) (95% CI)</strong></td>
<td>2.5% (2.3 to 2.7)</td>
</tr>
<tr>
<td><strong>NPV (%) (95% CI)</strong></td>
<td>99.8% (99.8 to 99.8)</td>
</tr>
<tr>
<td><em><em>Calibration slope</em> (95% CI)</em>*</td>
<td>0.782 (0.743 to 0.824)</td>
</tr>
<tr>
<td><strong>Brier score</strong></td>
<td>0.069</td>
</tr>
</tbody>
</table>

* Calibration slope was derived from linear regression models by forcing the intercept through origin (0, 0).

AF, atrial fibrillation; AUROC, area under the receiver operating characteristic; CHA₂DS₂-VASc, Congestive heart failure, Hypertension, Age >75 (2 points), Stroke/transient ischaemic attack/thromboembolism (2 points), Vascular disease, Age 65–74, Sex category; C_HEST, Coronary artery disease/Chronic obstructive pulmonary disease (1 point each), Hypertension, Elderly (age ≥75, 2 points), Systolic heart failure, Thyroid disease (hyperthyroidism); FIND-AF, Future Innovations in Novel Detection of Atrial Fibrillation; MLR, multivariable logistic regression; NPV, negative predictive value; PPV, positive predictive value. 

Figure 1: The top 10 most important variables for FIND-AF prediction in individuals aged ≥30 years quantified by mean decrease in Gini coefficient. COPD, chronic obstructive pulmonary disease; EP, electrophysiology; FIND-AF, Future Innovations in Novel Detection of Atrial Fibrillation; IHF, ischaemic heart disease.
Arrhythmias and sudden death

arrived at.\textsuperscript{21} FIND-AF has been designed to be implemented and displayed through EHR systems, so will be available in a platform that healthcare professionals are interacting with as part of routine care. By design, FIND-AF provides AF risk prediction over a short time frame and so could assist clinicians at point of care in identifying patients for targeted diagnostics such as ECG.

Figure 2 Receiver operating characteristic curves for FIND-AF, the multivariable logistic regression (MLR), CHA\textsubscript{2}DS\textsubscript{2}-VASc and C\textsubscript{HEST} algorithm.

C\textsubscript{HEST}, Coronary artery disease/Chronic obstructive pulmonary disease (1 point each), Hypertension, Elderly (age $\geq$75, 2 points), Systolic heart failure, Thyroid disease (hyperthyroidism); CHA\textsubscript{2}DS\textsubscript{2}-VASc, Congestive heart failure, Hypertension, Age >75 (2 points), Stroke/transient ischaemic attack/thromboembolism (2 points), Vascular disease, Age 65–74, Sex category.

Figure 3 Kaplan-Meier plots for AF occurrence, by predicted risk from FIND-AF. AF, atrial fibrillation; FIND-AF, Future Innovations in Novel Detection of Atrial Fibrillation.

Arrhythmias and sudden death

Finally, the most important predictors in FIND-AF are already well-recognised risk factors for AF (for example, age, heart failure, valvular heart disease), which provide reassurance in the associations being made by the algorithm.7

Fairness is a critical characteristic when considering the impact of prediction algorithms in healthcare. The CHARGE-AF and PuLSE-AI algorithms have strong AF prediction performance,9 11 yet incorporate variables that are frequently missing (height, weight and systolic and diastolic blood pressure).10 Consequently, their applicability is limited to 17% and 35% of primary care EHRs, respectively.9 11 Often, health data poverty disproportionately affects individuals from minority ethnicities and deprived backgrounds, so the application of these algorithms could reinforce health inequities.22 Furthermore, whether their performance varies by sex and in minority ethnic groups in European populations is unknown. In our study, the C2HEST and CHA2DS2-VASc scores were less accurate in women compared with men, and their performance varied substantially across different ethnic groups. FIND-AF’s design enabled its application to every single patient record in a nationally representative sample.

### Table 3  Discrimination performance of FIND-AF, CHA2DS2-VASc and C2HEST by sex, age and ethnicity

<table>
<thead>
<tr>
<th></th>
<th>FIND-AF (AUROC, 95% CI)</th>
<th>CHA2DS2-VASc (AUROC, 95% CI)</th>
<th>C2HEST (AUROC, 95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>0.824 (0.814 to 0.834)</td>
<td>0.784 (0.773 to 0.794)</td>
<td>0.757 (0.744 to 0.770)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>0.819 (0.809 to 0.829)</td>
<td>0.807 (0.793 to 0.821)</td>
<td>0.793 (0.777 to 0.810)</td>
</tr>
<tr>
<td>Women</td>
<td>0.821 (0.810 to 0.831)</td>
<td>0.776 (0.760 to 0.793)</td>
<td>0.746 (0.727 to 0.765)</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥65 years</td>
<td>0.712 (0.698 to 0.727)</td>
<td>0.669 (0.654 to 0.684)</td>
<td>0.675 (0.661 to 0.690)</td>
</tr>
<tr>
<td>≥75 years</td>
<td>0.657 (0.638 to 0.675)</td>
<td>0.612 (0.593 to 0.632)</td>
<td>0.589 (0.570 to 0.608)</td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>0.810 (0.799 to 0.821)</td>
<td>0.781 (0.769 to 0.792)</td>
<td>0.756 (0.743 to 0.770)</td>
</tr>
<tr>
<td>Asian</td>
<td>0.796 (0.693 to 0.899)</td>
<td>0.758 (0.639 to 0.876)</td>
<td>0.731 (0.611 to 0.850)</td>
</tr>
<tr>
<td>Black</td>
<td>0.801 (0.680 to 0.923)</td>
<td>0.843 (0.764 to 0.923)</td>
<td>0.707 (0.511 to 0.902)</td>
</tr>
<tr>
<td>Other non-white ethnic minority</td>
<td>0.805 (0.765 to 0.845)</td>
<td>0.768 (0.729 to 0.807)</td>
<td>0.805 (0.765 to 0.846)</td>
</tr>
<tr>
<td>Ethnicity unrecorded</td>
<td>0.823 (0.770 to 0.875)</td>
<td>0.838 (0.777 to 0.900)</td>
<td>0.788 (0.705 to 0.870)</td>
</tr>
</tbody>
</table>

The total number of individuals in each subgroup and number of incident AF cases are as follows: men (n=211 378, AF=720), women (n=204 850, AF=753), age ≥65 years (n=81 258, AF=1168), age ≥75 years (n=36 358, AF=796), white (n=279 027, AF=1301), Asian (n=8422, AF=16), black (n=6478, AF=11), other non-white ethnic minority (n=93 998, AF=731), ethnicity unrecorded (n=93 998, AF=49).

AF, atrial fibrillation; AUROC, area under the receiver operating characteristic; CHA2DS2-VASc, Congestive heart failure, Hypertension, Age >75 (2 points), Stroke/transient ischaemic attack/thromboembolism (2 points), Vascular disease, Age 65–74, Sex category; C2HEST, Coronary artery disease/Chronic obstructive pulmonary disease (1 point each), Hypertension, Elderly (age ≥75, 2 points), Systolic heart failure, Thyroid disease (hyperthyroidism); FIND-AF, Future Innovations in Novel Detection of Atrial Fibrillation.

Figure 4  Summary of the study and main findings. Hitherto implementation of screening for atrial fibrillation (AF) has been targeted to older persons in the general population, but this may miss one-fifth of new cases. A machine learning algorithm using routinely collected data in primary care electronic health records in the UK can accurately predict short-term risk of AF in persons aged ≥30 years. This may be a more efficient method for guiding AF screening. C2HEST, Coronary artery disease/Chronic obstructive pulmonary disease (1 point each), Hypertension, Elderly (age ≥75, 2 points), Systolic heart failure, Thyroid disease (hyperthyroidism); CHA2DS2-VASc, Congestive heart failure, Hypertension, Age ≥75 (2 points), Stroke/transient ischaemic attack/thromboembolism (2 points), Vascular disease, Age 65–74, Sex category; FIND-AF, Future Innovations in Novel Detection of Atrial Fibrillation.
defined higher-rates, compared with routine care. However, the yield of new screening guided by age has not been demonstrated to increase of clinic and prescription of oral anticoagulation, after the mixed results associated with elevated AF occurrence both in the short and long term. Therefore, FIND-AF could facilitate efficient population-based AF screening or comprehensive programmes designed to improve risk factor profiles (including targeted weight loss and optimisation of blood pressure control). Screening for AF would adhere to many of the Wilson and Junger principles for a screening programme. Opportunistic screening guided by age has not been demonstrated to increase AF detection rates, but this may change in a more precisely defined higher-risk cohort. Systematic screening of older patients with intermittent or continuous (invasive or non-invasive) rhythm monitors is associated with increased AF detection rates, compared with routine care. However, the yield of new cases is low (3% in the STROKESTOP trial) and in our study, FIND-AF more efficiently identified a cohort with a higher rate of clinically detected AF than age-based approaches. Accurate risk assessment would be an integral component of a systematic screening process but ongoing research is needed to address the issues of the effectiveness and safety of treatment of screen-detected AF, and the costs of widespread use of ECG monitoring and prescription of oral anticoagulation, after the mixed results of the recently published LOOP and STROKESTOP trials.

There are some limitations to our study. First, the CPRD database is routinely collected, retrospective primary care data. Underestimation of AF incidence is possible since there will have been individuals with unrecorded asymptomatic AF. Second, important predictor variables may have been ‘missing data’. Underestimation of AF incidence is possible since there will have been individuals with unrecorded asymptomatic AF. Third, the cohort identified as higher risk in this study included younger people who would currently be excluded from screening pathways, and higher predicted AF risk was associated with elevated AF occurrence both in the short and long term. Therefore, FIND-AF could facilitate efficient population-based AF screening or comprehensive programmes designed to improve risk factor profiles (including targeted weight loss and optimisation of blood pressure control).

CONCLUSIONS

We trained and tested a novel machine learning algorithm (FIND-AF) that was applicable at scale within a nationwide routinely collected primary care EHR dataset. FIND-AF was able to accurately predict AF risk within 6 months and identify a cohort at elevated risk of AF in the longer term.

Author affiliations

1 Leeds Institute for Data Analytics, University of Leeds, Leeds, UK
2 Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK
3 Department of Dentistry, University of Leeds, Leeds, UK
4 School of Computing, University of Leeds, Leeds, UK
5 Faculty of Medicine and Health, University of Leeds, Leeds, UK
6 Maximizing Health Outcomes Research Lab, Sapir College, Hof Ashkelon, Israel
7 Community Medical Services Division, Clalit Health Services, Tel Aviv, Israel
8 Department of Cardiology, Soroka University Medical Center, Beer Sheva, Israel
9 Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
10 Cardiology, Soroka Medical Center, Beer Sheva, Israel
11 The Phoenix Partnership, Leeds, UK
12 Cardiology, Leeds General Infirmary, Leeds, UK

Twitter Ramesh Nadarajah @Dr_R_Nadarajah, Jianhua Wu @jianhuawu6, Keerthenan Raveendra @keerthevaraveendra, Yoko M Nakao @YokoMNakao and Chris P Gale @cp_gale3

Acknowledgements We acknowledge the tremendous help of all members of the FIND-AF scientific advisory board and FIND-AF patient and public involvement group in directing this project to greatest clinical utility.

Contributors RN, JW and CP conceived the idea of the study. JW undertook data extraction and statistical analysis. RN verified the underlying data. RN, JW and CP interpreted the findings and RN drafted the manuscript. CB, JP, DH, CC, KR, YMN, KN, DZ, RA, MH, JW and CP critically reviewed the manuscript and RN revised the manuscript for final submission. All authors had full access to all data in the study and accept responsibility to submit for publication. RN is the guarantor.

Funding RN is supported by the British Heart Foundation Clinical Research Training Fellowship (FS/20/12/34789).

Competing interests All authors have completed the ICMJE uniform disclosure form at www.icmje.org/col_disclosure.pdf and declare support from the British Heart Foundation for the submitted work. CP has received grants for research from the British Heart Foundation, National Institute for Health Research, Horizon 2020, Abbott Diabetes, Bristol Myers Squibb and European Society of Cardiology; consulting fees from AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer-Ingelheim, Boston Scientific, Chiesi, Daiichi Sankyo, Menarini and Organon; honoraria for speaking at meetings and educational events from AstraZeneca, Menarini, Novartis, Raisio Group, Vanda Medical and Zydus; support for attending meetings from Bayer and Bristol Myers Squibb; and has acted as an advisory board member for Amgen, AstraZeneca, Bayer, Bristol Myers Squibb and Boehringer-Ingelheim, Chiesi, Daiichi Sankyo, Menarini, Novartis and iRhythm. YMN has received advisory fees and a research grant from Bayer.

Patient and public involvement Patients and/or the public were involved in the design, conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Not required.

Ethics approval Ethical approval was granted by the Independent Scientific Advisory Committee (ISAC) of the Medicines and Healthcare Products Regulatory Agency (ref no: 19_076).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data may be obtained from a third party and are not publicly available. Data used in this study can be accessed through CPRD subject to protocol approval. The algorithm can be shared with researchers who agree to use it only for research purposes with a data sharing agreement.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and that you indicate the author(s) and BMJ.


Downloaded from http://heart.bmj.com/ on June 7, 2023 by guest. Protected by copyright.
and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iDs
Ramesh Nadarajah http://orcid.org/0000-0001-9895-9356
Jianhua Wu http://orcid.org/0000-0001-6093-599X
Yoko M Nakao http://orcid.org/0000-0002-3627-5626
Ronen Arbel http://orcid.org/0000-0002-6058-8665
Chris Bates http://orcid.org/0000-0003-0113-2593

REFERENCES